Ascendis Pharma A/S (NASDAQ:ASND) Trading Up 4.4% - Here's Why

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) shot up 4.4% during trading on Friday . The company traded as high as $160.97 and last traded at $167.52. 43,165 shares were traded during trading, a decline of 91% from the average session volume of 486,169 shares. The stock had previously closed at $160.45.

Analyst Ratings Changes

ASND has been the topic of several research analyst reports. Cantor Fitzgerald lifted their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. UBS Group started coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Finally, Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Trading Up 1.1 %

The stock's fifty day simple moving average is $154.21 and its 200-day simple moving average is $139.47. The company has a market capitalization of $10.27 billion, a price-to-earnings ratio of -23.72 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the fourth quarter worth approximately $28,000. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth $30,000. Jones Financial Companies Lllp increased its stake in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. increased its stake in Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.